Cellumen is the cellular systems biology company dedicated to helping researchers create greater numbers of efficacious, safe, and patient-targeted drugs. How Cellumen will Contribute to the DSEC community: Cellumen’s subject matter expertise uses a combination of toxicity-relevant cells and toxicity biomarkers to illuminate cellular system responses to toxic challenges in a specially designed set of panels. Read more.
Capability Overview: Cellumen analyzes the systems response of cell lines, primary cells, and patient samples to drug treatments. By addressing the complexity of cellular system responses Cellumen can prioritize lead series and improve safety to a significant degree. Learn more here.
Subject Matter Experts: Lans Taylor, Ph.D., President and CEO, Kenneth A. Giuliano, Ph. D., Principal Scientist, Albert Gough, Ph.D., Vice-President, Discovery Technology, Kate Johnston, Ph.D., Vice-President, Discovery Programs
Website: www.cellumen.com